Skip to main content
. Author manuscript; available in PMC: 2014 Nov 14.
Published in final edited form as: Leuk Res. 2013 Jul 25;37(11):1440–1444. doi: 10.1016/j.leukres.2013.07.007

Table 4.

Baseline Clinical Characteristics of Patients Who Received Pomalidomide 0.5 mg/day (N = 29)

Characteristic Number (%)/ Median
Age (years) 68 [39–86]
Male 14 (48%)
Diagnosis
 PMF 20 (69%)
 Post-ET MF 8 (28%)
 Post-PV MF 1 (3%)
Splenomegaly 11 (38%)
Hemoglobin, g/dL 9.0 [7.1–11.1]
White Blood Cell Count × 109/L 6.0 [2.0–21.7]
Platelets × 109/L 224.0 [53.0–1478.0]
JAK 2 V617 F mutated 17 (59%)
Karyotype
 Diploid 20 (69%)
 Abnormal 8 (28%)
 Indeterminate 1 (3%)
Prior treatment 19 (65%)

Abbreviations: PMF, primary myelofibrosis; Post-ET MF, post essential thrombocytosis myelofibrosis; post-PV MF, post polycythemia vera myelofibrosis.